The firm is a Japanese technology-based distributor and service solution provider of electronic components, enterprise IT and innovative solutions. Headquartered in Japan, the company operates 85 offices worldwide. The firm’s main business domains lie in semiconductors, IoT and cybersecurity, but seeks to expand beyond these realms to create new businesses, including healthcare, life sciences. The firm has been making strategic investments periodically to make business partnership with external technology startups from all around the world that align with the firm’s interests. The firm’s investment is stage agnostic but mostly between Seed and Series B financing rounds. The firm is open to business partnership and global investment opportunities from any country.
Within life sciences and healthcare, the firm is open to opportunities in digital therapeutics, devices, and digital health. Within therapeutics, the firm is primarily seeking enabling technologies in chronic diseases as diabetes, sleep disorders, mental health, and also depression and dementia. The firm will generally not consider opportunities such as pre-clinical antibody or small molecule assets that require a long window. The firm is also interested in devices (open to both 510k and PMA) or digital health technologies that are in the fields of primary care, elderly care, and mental health. Some examples of The firm’s investments include a continuous glucose monitoring device, an AI-driven robotics platform for chronic care management, and a digital therapeutics app for chronic diseases. While the firm can invest in very early-stage companies, the firm prefers to invest in companies with a viable product that is ready to be tested in pilots or clinical trials at the earliest. The firm does not
expect companies to have already received FDA approval and will help companies go through the regulatory process. Furthermore, the firm has an ongoing strategic partnership with the Japanese Organization for Medical Device Development (JOMDD), through which the firm helps companies with PMDA approval in Japan.
The firm has no specific company or management team requirements, and prefers to act as a co-investor. The firm does not require or seek board representation. As a completely strategic investor, the firm seeks to invest in companies that align with the firm’s new business goals and those that the firm can provide a strong value-add.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply